The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1705
June 24, 2024
View Complete Issue         Table of Contents 2019 
Gepirone (Exxua) for Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Gepirone (Exxua) for Depression
June 24, 2024 (Issue: 1705)
The FDA has approved an oral extended-release formulation of gepirone (Exxua – Fabre-Kramer), a selective 5-HT1A receptor agonist, for treatment of major depressive disorder (MDD) in adults. Gepirone was originally developed decades ago for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Gepirone (Exxua) for Depression
Article code: 1705a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.